00:37 , May 10, 2019 |  BC Innovations  |  Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

Congress has taken the first step towards fixing a key problem with patent policy that has crippled the diagnostics industry and disrupted development of other life science inventions, but its proposed solution falls short for...
19:42 , May 2, 2019 |  BC Extra  |  Financial News

May 2 Financial Quick Takes: Magenta, Clovis, Atomwise

Magenta follow-on comes with haircut  Stem cell transplant company Magenta Therapeutics Inc. (NASDAQ:MGTA) raised $56.3 million in a follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow. At $13.25 per share, the price...
19:06 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round on Oct. 19 and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational...
12:26 , Oct 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
04:17 , Oct 13, 2018 |  BioCentury  |  Product Development

Trevena goes for MOR than morphine

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee meeting on pain candidate oliceridine from Trevena Inc. gave the agency little reason to reverse its skepticism about the molecule’s benefits and risks. But it did leave...
21:55 , Jun 27, 2018 |  BC Extra  |  Clinical News

Lynparza meets in first-line ovarian cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib as a first-line maintenance therapy improved progression-free survival (PFS) vs. placebo in patients with BRCA-mutated advanced ovarian cancer, meeting the primary...
19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

MeiraGTx trades flat after $75M IPO

Gene therapy play MeiraGTx Holdings plc (NASDAQ:MGTX) shares were unchanged June 8 after the company raised $75 million via the sale of 5 million shares at $15 in an IPO underwritten by BofA Merrill Lynch,...
12:47 , Jun 8, 2018 |  BC Extra  |  Financial News

MeiraGTx trades flat after $75M IPO

Gene therapy play MeiraGTx Holdings plc (NASDAQ:MGTX) shares were unchanged Friday after the company raised $75 million via the sale of 5 million shares at $15 in an IPO underwritten by BofA Merrill Lynch, Barclays,...
19:09 , May 18, 2018 |  BC Week In Review  |  Financial News

MeiraGTx proposes $86.3M IPO

MeiraGTx Holdings plc (New York, N.Y.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Barclays, Evercore ISI and Chardan. The company is developing a portfolio of...
22:17 , May 15, 2018 |  BC Extra  |  Financial News

MeiraGTx plans IPO

MeiraGTx Holdings plc (New York, N.Y.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Barclays, Evercore ISI and Chardan. The company is developing a portfolio of...